Background: Exercise therapy plays an important role in the prevention and treatment of type 2 diabetes (T2DM). The mechanism of exercise therapy in the improvement of glycolipid metabolism of T2DM is very complex and not completely clear. Summary: Exercise training improves the whole body metabolic health in patients with T2DM, leading to an increase in glycolipid uptake and utilization, improved insulin sensitivity, optimized body mass index, and modulated DNA methylation, etc. Recent findings support that some cytokines such as irisin, osteocalcin, and adiponectin are closely related to exercise and metabolic diseases. This study briefly reviews the physiological mechanisms of exercise therapy in diabetes and the potential role of these cytokines in exercise. Key Messages: More high-quality, targeted, randomized controlled studies are needed urgently, from mechanism study to treatment direction, to provide a more theoretical basis for exercise therapy and to explore new therapeutic targets for diabetes.

1.
Xu Y, Wang L, He J, Bi Y, Li M, Wang T, et al.; 2010 China Noncommunicable Disease Surveillance Group. Prevalence and control of diabetes in Chinese adults.
JAMA
. 2013 Sep;310(9):948–59.
2.
Hamasaki H. Daily physical activity and type 2 diabetes: A review.
World J Diabetes
. 2016 Jun;7(12):243–51.
3.
Thent ZC, Das S, Henry LJ. Role of exercise in the management of diabetes mellitus: the global scenario.
PLoS One
. 2013 Nov;8(11):e80436.
4.
Tang JL, Li XY, Yuan L, Han J, Ju CP, et al. Correlation of regular exercise with metabolic control and reduced chronic complications in type 2 diabetic patients.
Chin J Diabetes Mellitus
. 2015:136–41.
5.
Dos Santos JM, Moreli ML, Tewari S, Benite-Ribeiro SA. The effect of exercise on skeletal muscle glucose uptake in type 2 diabetes: an epigenetic perspective.
Metabolism
. 2015 Dec;64(12):1619–28.
6.
Stanford KI, Goodyear LJ. Exercise and type 2 diabetes: molecular mechanisms regulating glucose uptake in skeletal muscle.
Adv Physiol Educ
. 2014 Dec;38(4):308–14.
7.
Hussey SE, McGee SL, Garnham A, McConell GK, Hargreaves M. Exercise increases skeletal muscle GLUT4 gene expression in patients with type 2 diabetes.
Diabetes Obes Metab
. 2012 Aug;14(8):768–71.
8.
Gordon JW, Dolinsky VW, Mughal W, Gordon GR, McGavock J. Targeting skeletal muscle mitochondria to prevent type 2 diabetes in youth.
Biochem Cell Biol
. 2015 Oct;93(5):452–65.
9.
Stepto NK, Benziane B, Wadley GD, Chibalin AV, Canny BJ, Eynon N, et al. Short-term intensified cycle training alters acute and chronic responses of PGC1α and Cytochrome C oxidase IV to exercise in human skeletal muscle.
PLoS One
. 2012;7(12):e53080.
10.
Fonseca RM, Roschel H, Tricoli V, de Souza EO, Wilson JM, Laurentino GC, et al. Changes in exercises are more effective than in loading schemes to improve muscle strength.
J Strength Cond Res
. 2014 Nov;28(11):3085–92.
11.
Kristiansen MS, Uhrbrand A, Hansen M, Shiguetomi-Medina JM, Vissing K, Stødkilde-Jørgensen H, et al. Concomitant changes in cross-sectional area and water content in skeletal muscle after resistance exercise.
Scand J Med Sci Sports
. 2014 Aug;24(4):e260–8.
12.
Teixeira-Lemos E, Nunes S, Teixeira F, Reis F. Regular physical exercise training assists in preventing type 2 diabetes development: focus on its antioxidant and anti-inflammatory properties.
Cardiovasc Diabetol
. 2011 Jan;10(1):12.
13.
Solomon TP, Malin SK, Karstoft K, Kashyap SR, Haus JM, Kirwan JP. Pancreatic β-cell function is a stronger predictor of changes in glycemic control after an aerobic exercise intervention than insulin sensitivity.
J Clin Endocrinol Metab
. 2013 Oct;98(10):4176–86.
14.
Mullugeta Y, Chawla R, Kebede T, Worku Y. Dyslipidemia associated with poor glycemic control in type 2 diabetes mellitus and the protective effect of metformin supplementation.
Indian J Clin Biochem
. 2012 Oct;27(4):363–9.
15.
Wu Y, Wu JF. Research progress in the mechanism of exercise therapy for prevention and treatment of type 2 diabetes mellitus.
Chin J Diabetes Mellitus
. 2015:184–6.
16.
Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes.
Diabetes Res Clin Pract
. 2014 Aug;105(2):141–50.
17.
Baker RG, Hayden MS, Ghosh S. NF-κB, inflammation, and metabolic disease.
Cell Metab
. 2011 Jan;13(1):11–22.
18.
Gleeson M, Bishop NC, Stensel DJ, Lindley MR, Mastana SS, Nimmo MA. The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease.
Nat Rev Immunol
. 2011 Aug;11(9):607–15.
19.
Karstoft K, Pedersen BK. Exercise and type 2 diabetes: focus on metabolism and inflammation.
Immunol Cell Biol
. 2016 Feb;94(2):146–50.
20.
Wang Y, Liu JY. Effect of aerobic exercise combined with resistance training on patients with abdominal obesity. Chin J Phys Med Rehab. 2013;231–232.
21.
Lee S, Bacha F, Hannon T, Kuk JL, Boesch C, Arslanian S. Effects of aerobic versus resistance exercise without caloric restriction on abdominal fat, intrahepatic lipid, and insulin sensitivity in obese adolescent boys: a randomized, controlled trial.
Diabetes
. 2012 Nov;61(11):2787–95.
22.
Rehm KE, Marshall GD. Relationship between immune biomarkers and both physical activity and stress levels in young and older adults. Brain, Behavior, and Immunity. 2015;49:e5.
23.
Langenberg C, Sharp SJ, Franks PW, Scott RA, Deloukas P, Forouhi NG, et al. Gene-lifestyle interaction and type 2 diabetes: the EPIC interact case-cohort study.
PLoS Med
. 2014 May;11(5):e1001647.
24.
Reddon H, Guéant JL, Meyre D. The importance of gene-environment interactions in human obesity.
Clin Sci (Lond)
. 2016 Sep;130(18):1571–97.
25.
Reddon H, Gerstein HC, Engert JC, Mohan V, Bosch J, Desai D, et al. Physical activity and genetic predisposition to obesity in a multiethnic longitudinal study.
Sci Rep
. 2016 Jan;6(1):18672.
26.
Richardson AS, North KE, Graff M, Young KM, Mohlke KL, Lange LA, et al. Moderate to vigorous physical activity interactions with genetic variants and body mass index in a large US ethnically diverse cohort.
Pediatr Obes
. 2014 Apr;9(2):e35–46.
27.
Xi B, Shen Y, Zhang M, Liu X, Zhao X, Wu L, et al. The common rs9939609 variant of the fat mass and obesity-associated gene is associated with obesity risk in children and adolescents of Beijing, China.
BMC Med Genet
. 2010 Jul;11(1):107.
28.
Cauchi S, Nead KT, Choquet H, Horber F, Potoczna N, Balkau B, et al. The genetic susceptibility to type 2 diabetes may be modulated by obesity status: implications for association studies.
BMC Med Genet
. 2008 May;9(1):45.
29.
van Dijk SJ, Molloy PL, Varinli H, Morrison JL, Muhlhausler BS; Members of EpiSCOPE. Epigenetics and human obesity.
Int J Obes
. 2015 Jan;39(1):85–97.
30.
Davegårdh C, García-Calzón S, Bacos K, Ling C. DNA methylation in the pathogenesis of type 2 diabetes in humans.
Mol Metab
. 2018 Aug;14:12–25.
31.
Barrès R, Yan J, Egan B, Treebak JT, Rasmussen M, Fritz T, et al. Acute exercise remodels promoter methylation in human skeletal muscle.
Cell Metab
. 2012 Mar;15(3):405–11.
32.
Rowlands DS, Page RA, Sukala WR, Giri M, Ghimbovschi SD, Hayat I, et al. Multi-omic integrated networks connect DNA methylation and miRNA with skeletal muscle plasticity to chronic exercise in Type 2 diabetic obesity.
Physiol Genomics
. 2014 Oct;46(20):747–65.
33.
Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis.
Nature
. 2012 Jan;481(7382):463–8.
34.
Besseiche A, Riveline JP, Gautier JF, Bréant B, Blondeau B. Metabolic roles of PGC-1α and its implications for type 2 diabetes.
Diabetes Metab
. 2015 Nov;41(5):347–57.
35.
Sanchez-Delgado G, Martinez-Tellez B, Olza J, Aguilera CM, Gil Á, Ruiz JR. Role of exercise in the activation of brown adipose tissue.
Ann Nutr Metab
. 2015;67(1):21–32.
36.
Zhang Y, Li R, Meng Y, Li S, Donelan W, Zhao Y, et al. Irisin stimulates browning of white adipocytes through mitogen-activated protein kinase p38 MAP kinase and ERK MAP kinase signaling.
Diabetes
. 2014 Feb;63(2):514–25.
37.
Shan T, Liang X, Bi P, Kuang S. Myostatin knockout drives browning of white adipose tissue through activating the AMPK-PGC1α-Fndc5 pathway in muscle.
FASEB J
. 2013 May;27(5):1981–9.
38.
Choi YK, Kim MK, Bae KH, Seo HA, Jeong JY, Lee WK, et al. Serum irisin levels in new-onset type 2 diabetes.
Diabetes Res Clin Pract
. 2013 Apr;100(1):96–101.
39.
Liu JJ, Wong MD, Toy WC, Tan CS, Liu S, Ng XW, et al. Lower circulating irisin is associated with type 2 diabetes mellitus.
J Diabetes Complications
. 2013 Jul-Aug;27(4):365–9.
40.
Huh JY, Panagiotou G, Mougios V, Brinkoetter M, Vamvini MT, Schneider BE, et al. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise.
Metabolism
. 2012 Dec;61(12):1725–38.
41.
Kim HJ, Lee HJ, So B, Son JS, Yoon D, Song W. Effect of aerobic training and resistance training on circulating irisin level and their association with change of body composition in overweight/obese adults: a pilot study.
Physiol Res
. 2016 Jun;65(2):271–9.
42.
Nygaard H, Slettaløkken G, Vegge G, Hollan I, Whist JE, Strand T, et al. Irisin in blood increases transiently after single sessions of intense endurance exercise and heavy strength training.
PLoS One
. 2015 Mar;10(3):e0121367.
43.
Fox J, Rioux BV, Goulet ED, Johanssen NM, Swift DL, Bouchard DR, et al. Effect of an acute exercise bout on immediate post-exercise irisin concentration in adults: A meta-analysis.
Scand J Med Sci Sports
. 2018 Jan;28(1):16–28.
44.
Kurdiova T, Balaz M, Vician M, Maderova D, Vlcek M, Valkovic L, et al. Effects of obesity, diabetes and exercise on Fndc5 gene expression and irisin release in human skeletal muscle and adipose tissue: in vivo and in vitro studies.
J Physiol
. 2014 Mar;592(5):1091–107.
45.
Roca-Rivada A, Castelao C, Senin LL, Landrove MO, Baltar J, Belén Crujeiras A, et al. FNDC5/irisin is not only a myokine but also an adipokine.
PLoS One
. 2013 Apr;8(4):e60563.
46.
Stengel A, Hofmann T, Goebel-Stengel M, Elbelt U, Kobelt P, Klapp BF. Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity–correlation with body mass index.
Peptides
. 2013 Jan;39:125–30.
47.
Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, et al. Endocrine regulation of energy metabolism by the skeleton.
Cell
. 2007 Aug;130(3):456–69.
48.
Liu JM, Rosen CJ, Ducy P, Kousteni S, Karsenty G. Regulation of glucose handling by the skeleton: insights from mouse and human studies.
Diabetes
. 2016 Nov;65(11):3225–32.
49.
Ferron M, McKee MD, Levine RL, Ducy P, Karsenty G. Intermittent injections of osteocalcin improve glucose metabolism and prevent type 2 diabetes in mice.
Bone
. 2012 Feb;50(2):568–75.
50.
Ng KW. Regulation of glucose metabolism and the skeleton.
Clin Endocrinol (Oxf)
. 2011 Aug;75(2):147–55.
51.
Ferron M, Lacombe J. Regulation of energy metabolism by the skeleton: osteocalcin and beyond.
Arch Biochem Biophys
. 2014 Nov;561:137–46.
52.
Levinger I, Jerums G, Stepto NK, Parker L, Serpiello FR, McConell GK, Anderson M, Hare DL, Byrnes E, Ebeling PR, Seeman E. The effect of acute exercise on undercarboxylated osteocalcin and insulin sensitivity in obese men.
J Bone Miner Res
. 2014 Dec;29(12):2571–6.
53.
Ferron M, Wei J, Yoshizawa T, Del Fattore A, DePinho RA, Teti A, et al. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism.
Cell
. 2010 Jul;142(2):296–308.
54.
Greenhill C. Exercise: osteocalcin in the adaptation to exercise.
Nat Rev Endocrinol
. 2016 Aug;12(8):434.
55.
Mera P, Laue K, Ferron M, Confavreux C, Wei J, Galán-Díez M, et al. Osteocalcin signaling in myofibers is necessary and sufficient for optimum adaptation to exercise.
Cell Metab
. 2016 Jun;23(6):1078–92.
56.
Shah K, Armamento-Villareal R, Parimi N, Chode S, Sinacore DR, Hilton TN, Napoli N, Qualls C, Villareal DT. Exercise training in obese older adults prevents increase in bone turnover and attenuates decrease in hip bone mineral density induced by weight loss despite decline in bone-active hormones.
J Bone Miner Res
. 2011 Dec;26(12):2851–9.
57.
Ma XY, Chen FQ, Hong H, Lv XJ, Dong M, Wang QY. The relationship between serum osteocalcin concentration and glucose and lipid metabolism in patients with type 2 diabetes mellitus – the role of osteocalcin in energy metabolism.
Ann Nutr Metab
. 2015;66(2-3):110–6.
58.
Kim YS, Nam JS, Yeo DW, Kim KR, Suh SH, Ahn CW. The effects of aerobic exercise training on serum osteocalcin, adipocytokines and insulin resistance on obese young males.
Clin Endocrinol (Oxf)
. 2015 May;82(5):686–94.
59.
Alfadda AA, Masood A, Shaik SA, Dekhil H, Goran M. Association between osteocalcin, metabolic syndrome, and cardiovascular risk factors: role of total and undercarboxylated osteocalcin in patients with type 2 diabetes.
Int J Endocrinol
. 2013;2013:197519.
60.
Colleluori G, Napoli N, Phadnis U, Armamento-Villareal R, Villareal DT. Effect of weight loss, exercise, or both on undercarboxylated osteocalcin and insulin secretion in frail, obese older adults.
Oxid Med Cell Longev
. 2017;2017:4807046.
61.
Wang ZV, Scherer PE. Adiponectin, the past two decades.
J Mol Cell Biol
. 2016 Apr;8(2):93–100.
62.
Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease.
Nat Rev Immunol
. 2011 Feb;11(2):85–97.
63.
Lee S, Kwak HB. Role of adiponectin in metabolic and cardiovascular disease.
J Exerc Rehabil
. 2014 Apr;10(2):54–9.
64.
Omae T, Nagaoka T, Tanano I, Yoshida A. Adiponectin-induced dilation of isolated porcine retinal arterioles via production of nitric oxide from endothelial cells.
Invest Ophthalmol Vis Sci
. 2013 Jul;54(7):4586–94.
65.
Katsiki N, Mantzoros C, Mikhailidis DP. Adiponectin, lipids and atherosclerosis.
Curr Opin Lipidol
. 2017 Aug;28(4):347–54.
66.
Pal China S, Sanyal S, Chattopadhyay N. Adiponectin signaling and its role in bone metabolism.
Cytokine
. 2018 Dec;112:116–31.
67.
Naot D, Musson DS, Cornish J. The activity of adiponectin in bone.
Calcif Tissue Int
. 2017 May;100(5):486–99.
68.
Yu N, Ruan Y, Gao X, Sun J. Systematic review and meta-analysis of randomized, controlled trials on the effect of exercise on serum leptin and adiponectin in overweight and obese individuals.
Horm Metab Res
. 2017 Mar;49(3):164–73.
69.
Zhang LY, Liu T, Teng YQ, Yao XY, Zhao TT, Lin LY, et al. Effect of a 12-week aerobic exercise training on serum fetuin-a and adipocytokine levels in type 2 diabetes. Exp Clin Endocrinol Diabetes. 2018 Sep;126(8):487–92.
70.
Jeon JY, Han J, Kim HJ, Park MS, Seo DY, Kwak YS. The combined effects of physical exercise training and detraining on adiponectin in overweight and obese children.
Integr Med Res
. 2013 Dec;2(4):145–50.
71.
Mendham AE, Duffield R, Marino F, Coutts AJ. A 12-week sports-based exercise programme for inactive Indigenous Australian men improved clinical risk factors associated with type 2 diabetes mellitus.
J Sci Med Sport
. 2015 Jul;18(4):438–43.
72.
Bouassida A, Chamari K, Zaouali M, Feki Y, Zbidi A, Tabka Z. Review on leptin and adiponectin responses and adaptations to acute and chronic exercise.
Br J Sports Med
. 2010 Jul;44(9):620–30.
73.
Huan CH, Chen JQ, Lin JX, Chen CX, Chen Q, Yang F, et al.
Exercise-induced insulin resistance improvement related to the changes of serum adiponectin,leptin and their interaction
. China Sport Science and Technology. 2011:100–5.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.